Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Side effects of therapy for chronic hepatitis C.

Russo MW, Fried MW.

Gastroenterology. 2003 May;124(6):1711-9. Review. No abstract available.

PMID:
12761728
2.

Hematologic side effects of PEG interferon and ribavirin. Management with growth factors.

Keeffe EB, Kowdley KV.

J Clin Gastroenterol. 2005 Jan;39(1 Suppl):S1-2. No abstract available.

PMID:
15597022
3.

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.

Infection. 2008 Jun;36(3):250-5. doi: 10.1007/s15010-007-7132-6. Epub 2008 May 3.

PMID:
18458815
4.

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Horta E Vale A, Wintfeld N, Green J.

J Hepatol. 2004 Apr;40(4):675-81.

PMID:
15030985
5.

Safety of peginterferon in the treatment of chronic hepatitis C.

Hashemi N, Rossi S, Navarro VJ, Herrine SK.

Expert Opin Drug Saf. 2008 Nov;7(6):771-81. doi: 10.1517/14740330802423291 . Review.

PMID:
18983223
6.

[Complementary treatments of chronic viral hepatitis C].

Thevenot T, Di Martino V, Lunel-Fabiani F, Vanlemmens C, Becker MC, Bronowicki JP, Bresson-Hadni S, Miguet JP.

Gastroenterol Clin Biol. 2006 Feb;30(2):197-214. Review. French.

7.

Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?

Balestrieri C, Serra G, Cauli C, Chessa L, Balestrieri A, Farci P.

Blood. 2006 Apr 15;107(8):3409-10. No abstract available.

8.

[Adverse reactions of different treatments in chronic hepatitis C].

Luca C, Grigore L, Vâţă A, Dorobăţ C.

Rev Med Chir Soc Med Nat Iasi. 2009 Oct-Dec;113(4):991-5. Romanian.

PMID:
20191864
9.

The management of side-effects during therapy for hepatitis C.

Aspinall RJ, Pockros PJ.

Aliment Pharmacol Ther. 2004 Nov 1;20(9):917-29. Review.

10.

[Type 1 diabetes developing during alpha-interferon therapy: report of two cases].

Vinagre I, Rigla M, Torras X, Enríquez J, Corcoy R.

Endocrinol Nutr. 2010 Oct;57(8):393-5. doi: 10.1016/j.endonu.2010.03.016. Epub 2010 May 11. Spanish. No abstract available.

PMID:
20462813
11.
12.

Hematologic side effects of interferon and ribavirin therapy.

Kowdley KV.

J Clin Gastroenterol. 2005 Jan;39(1 Suppl):S3-8. Review.

PMID:
15597025
13.

Gender influence on treatment of chronic hepatitis C genotype 1.

Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, Ferraz ML, Silva AE.

Rev Soc Bras Med Trop. 2010 May-Jun;43(3):217-23.

14.

Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.

[No authors listed]

Ann Intern Med. 2004 Mar 2;140(5):I67. No abstract available.

PMID:
14996694
15.

Short-duration therapy for hepatitis C: suitable for all?

Mangia A.

J Viral Hepat. 2007 Apr;14(4):221-7. Review.

PMID:
17381713
16.

[Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].

[No authors listed]

MMW Fortschr Med. 2002 Sep 19;144(38):59. German. No abstract available.

PMID:
12395712
17.

Entering the new era of therapy for HBV and HCV infections.

Peters MG, Perrillo RP, Jacobson IM, Ross DB, Doo EC, Murray JS, Wong JB.

J Fam Pract. 2010 Apr;59(4 Suppl):S51-8. No abstract available.

PMID:
20398591
18.

Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.

Sagir A, Wettstein M, Heintges T, Häussinger D.

Dig Dis Sci. 2002 Mar;47(3):562-3. No abstract available.

PMID:
11911342
19.
20.

[Combination therapy for chronic viral hepatitis C].

Zeuzem S.

Dtsch Med Wochenschr. 2003 Feb 21;128(8):370-4. Review. German. No abstract available.

PMID:
12594622
Items per page

Supplemental Content

Write to the Help Desk